ResearcherCentre Hospitalier Universitaire VaudoisActive in the last 2 years

Lana Elias Kandalaft

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1575-6674; OpenAlex author ID A5007749781. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 2)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 4

Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 2

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Antonia Digklia · 2 shared papers, 2019–2026 · strength 0.51
- Paper Strategies to develop therapeutic cancer vaccines for pancreatic cancer. DOI 10.1016/s2468-1253(26)00149-4 ↗
- Paper A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Ad… DOI 10.3389/fimmu.2019.01832 ↗
Matilde M. Coppi · 1 shared paper, 2026 · strength 0.43
- Paper Strategies to develop therapeutic cancer vaccines for pancreatic cancer. DOI 10.1016/s2468-1253(26)00149-4 ↗
Nicolas Demartines · 1 shared paper, 2019 · strength 0.08
- Paper A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Ad… DOI 10.3389/fimmu.2019.01832 ↗
Michal Bassani‐Sternberg · 1 shared paper, 2019 · strength 0.08
- Paper A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Ad… DOI 10.3389/fimmu.2019.01832 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.